Brief description not available

Brief description not available

The aim of this work is to target the production of age-specific production of hyperactive platelets as a therapeutic platform to control clot formation that causes thrombosis, stroke, heart attacks, and other cardiovascular disease, as well as platelet overproduction disorders such as essential thrombocytosis. In particular, this effort specifically targets cells that have progressed down an age-specific differentiation pathway. These age specific platelets are hyperactive relative to platelets from younger progenitor cells. These older platelet progenitor cells have been characterized molecularly and functionally characterization and can be targeted using pharmacological, antibody-based, cell based or gene therapy based strategies to control clot formation and platelet activity and numbers.

Researchers at the University of California, Davis have developed ibogaine-related compounds that promote neural plasticity and treat neuropsychiatric and neurological disorders.

Researchers at the University of California, Davis have developed a targeted gene editing system that reactivates the silenced CDKL5 gene by precise epigenetic modulation to treat CDKL5 deficiency disorder (CDD).

Researchers at the University of California, Davis have developed non-hallucinogenic compounds with clinically relevant therapeutic efficacy that promote neural growth and plasticity.

Researchers at the University of California, Davis have developed a class of compounds intended for the treatment of neurodegenerative diseases such as Alzheimer's by inhibiting DYRK1A kinase and modulating 5-HT2Rs.

MCFAs provide a synergistic bactericidal effect in combination with antibiotics and bacteriophages to effectively treat antibiotic-resistant bacterial infections.

Brief description not available

Brief description not available

Researchers at the University of California, Davis have developed a therapy that combines bioactive lipids with antiretroviral drugs to accelerate viral suppression and promote gut mucosal repair in HIV treatment.

Researchers at the University of California, Davis have developed a novel hybrid microbial-derived oxylipin and endocannabinoid-like molecule designed to enhance gut and brain health by improving barrier integrity, reducing inflammation, and providing neuroprotection.

Researchers at the University of California, Davis have developed a unique non-sacrificial synthetic peptide substrate designed to inhibit plasmin activity and prevent tumor progression and ascites formation in cancers characterized by elevated plasmin levels.

Researchers at the University of California, Davis have developed a method and composition that direct the growth of long, coronally oriented blood vessels in tissue grafts to improve vascularization and clinical transplant outcomes.

RNA-guided systems mediate diverse functions ranging from mobile genetic element propagation to adaptive immunity. These systems comprise proteins that use guide RNAs bearing sequence complementarity to nucleic acid substrates, facilitating programmable recognition of different substrates by the same protein or enzyme. In RNA-guided systems known to date, one or two continuous segments in the guideRNA determines target specificity and can be altered to direct the system to a new target, including genomic DNA in eukaryotic cells. However, there are constraints to such systems, e.g., protein size and the need for a protospacer adjacent motif (PAM) in target DNA. However, there is a need for nucleic acid guided systems that overcome constraints of known systems, such as protein size or protospacer adjacent motif.UC Berkeley researchers have developed a programmable RNA-guided nucleic acid targeting platform termed the Viral Interference Programmable Repeat (VIPR) system. The system employs a repeat-based guide RNA architecture and an associated targeting protein to direct sequence-specific recognition of nucleic acid substrates. Target specificity is programmable through modification of selected guide regions, enabling adaptable targeting of DNA or RNA substrates across different biological contexts, including cellular and viral genetic material.

A novel non-invasive therapy combining pulsed laser and dual-frequency ultrasound for rapid and precise treatment of port-wine stains.

The success of gene therapy relies heavily on the ability of delivery vehicles to reach specific cells without being intercepted by the immune system or accumulating in non-target organs. UC Berkeley researchers have developed engineered capsids for recombinant adeno-associated virus that are specifically optimized to target Schwann cells, which are the essential support cells of the peripheral nervous system. While naturally occurring varieties like adeno-associated virus 1 and adeno-associated virus 2 often struggle to infect these cells efficiently or are diverted to the liver, these new variant capsids show significantly increased infectivity in Schwann cells. Furthermore, they are designed to be more resistant to the neutralizing antibodies commonly found in humans, which can often render traditional viral treatments ineffective. This breakthrough enhances both the manufacturing potential and the safety profile of genetic treatments for peripheral nerve disorders.

The invention describes a platform technology that increases MHC presentation of oncogene derived peptide neoantigens that do not normally occur in the cell.  The platform has already been used to identify a method of increasing KRAS G12 D/V derived peptide presentation on MHC- I.

The central hurdle in the clinical translation of mRNA-based medicine is the inherent toxicity of the delivery vehicle. Standard Lipid Nanoparticles (LNPs) rely on cationic ionizable lipids that carry a positive charge at a pH of approximately 7.4, triggering aggressive pro-inflammatory responses and complement activation.  UC Berkeley researchers have developed a novel class of lipids engineered to resolve the "charge-toxicity" trade-off in nucleic acid delivery. Unlike conventional ionizable lipids that maintain a problematic positive charge density at physiological levels, these quaternized ionizable lipids are specifically tuned to remain neutral or negatively charged at a pH of approximately 7.4. They only transition to a positively charged state in acidic environments, such as the endosome, ensuring that the payload is released exactly where it is needed without alerting the immune system during systemic circulation. 

The core innovation is a dosimetry-driven approach that determines the activity concentration of a radioisotope based on the distance between the cement surface and the target tissue, enabling predictable, volume‑independent radiation dosing.

A novel high-affinity peptide selectively inhibits the human Kv1.5 channel to safely treat and prevent atrial fibrillation by targeting atrial electrophysiology.

Methods for treating bone tumors or other target tissues using radioisotopes mixed into a matrix material, most commonly bone cement.

Autoimmune disorders such as ankylosing spondylitis are heavily linked to specific genetic human tissue types, particularly variations of the human leukocyte antigen B27. Traditional treatments for these debilitating conditions often rely on broad immunosuppression, which weakens a patient's entire immune defense and increases the risk of infections. To provide a more precise solution, UC Berkeley researchers have developed small-molecule ligands that selectively target and block a specific disease-associated variation of this allele, known as human leukocyte antigen B27:05. The therapeutic compounds feature a distinct three-part molecular architecture that includes a targeted binding group designed to fit securely into a specific molecular pocket, a flexible chemical linker, and a reactive group that forms a stable bond with a neighboring cysteine amino acid residue. By turning off only the specific genetic driver responsible for the autoimmune reaction, this technology opens the door to highly targeted therapies that treat the root cause of the disease while leaving the rest of the immune system fully functional.

A highly precise and efficient gene-editing tool designed to correct single-nucleotide DNA mutations responsible for genetic diseases.

Researchers at the University of California, Davis have developed a novel nanobody specific for WISP2 that restores skeletal stem cell function to treat bone loss and promote bone growth in age-related bone diseases.